Q3 EPS Estimates for BioLife Solutions Cut by HC Wainwright

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings estimates for BioLife Solutions in a research report issued to clients and investors on Tuesday, May 27th. HC Wainwright analyst Y. Chen now expects that the medical equipment provider will earn $0.00 per share for the quarter, down from their previous estimate of $0.03. HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions' FY2026 earnings at ($0.01) EPS.

Separately, Wall Street Zen lowered BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Stock Down 2.2%

Shares of BLFS stock traded down $0.49 during trading hours on Wednesday, reaching $21.83. The company had a trading volume of 786,262 shares, compared to its average volume of 389,140. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -20.59 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions has a 12 month low of $18.70 and a 12 month high of $29.55. The business has a fifty day simple moving average of $22.94 and a 200-day simple moving average of $25.09.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC bought a new stake in shares of BioLife Solutions in the fourth quarter valued at $638,000. Alliancebernstein L.P. raised its stake in BioLife Solutions by 11.9% in the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider's stock valued at $970,000 after acquiring an additional 3,967 shares during the period. Envestnet Asset Management Inc. lifted its holdings in BioLife Solutions by 18.6% during the fourth quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider's stock valued at $5,158,000 after purchasing an additional 31,167 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in BioLife Solutions by 422.2% during the fourth quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider's stock valued at $5,684,000 after purchasing an additional 177,028 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its position in BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after purchasing an additional 519 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 25,687 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $582,067.42. Following the completion of the transaction, the chief financial officer now directly owns 189,242 shares of the company's stock, valued at $4,288,223.72. This represents a 11.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarah Aebersold sold 5,771 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86. Following the sale, the insider now owns 80,094 shares of the company's stock, valued at approximately $1,814,930.04. The trade was a 6.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,725 shares of company stock worth $1,710,666 in the last 90 days. Insiders own 2.20% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.